MRUS News and Press, Merus N.V. From 06/29/23

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ) for cancer, today announced that the U.S...

2023-06-17 23:06:34 ET Summary Merus has shown positive developments in clinical trials and regulatory meetings with the FDA, resulting in increased collaboration revenue and a more constructive investment outlook. Despite these positive factors, the company's current valuation of...

2023-06-15 07:56:47 ET Oncology company Merus ( NASDAQ: MRUS ) appointed Greg Perry CFO on June 14. Perry has also been designated as the company's principal financial officer, succeeding Bill Lundberg. Perry has served as a non-executive director of th...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the appointment of Greg ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D....

2023-05-04 17:54:55 ET Merus press release ( NASDAQ: MRUS ): Q1 GAAP EPS of -$0.86 beats by $0.17 . Revenue of $13.5M (+15.8% Y/Y) beats by $2.21M . For further details see: Merus GAAP EPS of -$0.86 beats by $0.17, revenue of $13.5M beats by $2.21M

– Petosemtamab clinical update presented at the American Association of Cancer Research (AACR) Annual Meeting 2023 – Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcin...

2023-04-17 12:55:02 ET Dutch biotech Merus ( NASDAQ: MRUS ) gained ~13% on Monday after announcing interim data for its bispecific antibody petosemtamab from a Phase 1/2 trial in previously treated head and neck squamous cell carcinoma (HNSCC). Citing a presentation at the o...

- 37% overall response rate (ORR) observed in 43 evaluable patients - 6 months median duration of response as of Feb. 1, 2023 data cutoff date - End-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor call on April 17...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced t...